blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2788348

EP2788348 - KINASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  25.08.2017
Database last updated on 09.07.2024
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Chiesi Farmaceutici S.p.A.
Via Palermo, 26/A
43100 Parma / IT
[2014/42]
Inventor(s)01 / VAN NIEL, Monique Bodil
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
02 / RAY, Nicholas Charles
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
03 / ALCARAZ, Lilian
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
04 / PANCHAL, Terry Aaron
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
05 / JENNINGS, Andrew Stephen Robert
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
06 / ARMANI, Elisabetta
Via Palermo 26/A
I-43100 Parma / IT
07 / CRIDLAND, Andrew Peter
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
08 / HURLEY, Christopher
Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
I-43100 Parma / IT
 [2014/42]
Representative(s)Minoja, Fabrizio
Bianchetti & Minoja S.r.l.
Via Plinio, 63
20129 Milano / IT
[N/P]
Former [2016/42]Minoja, Fabrizio
Bianchetti Bracco Minoja S.r.l.
Via Plinio, 63
20129 Milano / IT
Former [2014/42]Minoja, Fabrizio
Bianchetti Bracco Minoja S.r.l. Via Plinio, 63
20129 Milano / IT
Application number, filing date12808706.105.12.2012
[2016/42]
WO2012EP74450
Priority number, dateEP2011019289409.12.2011         Original published format: EP 11192894
EP2012018793210.10.2012         Original published format: EP 12187932
[2014/42]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013083606
Date:13.06.2013
Language:EN
[2013/24]
Type: A1 Application with search report 
No.:EP2788348
Date:15.10.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 13.06.2013 takes the place of the publication of the European patent application.
[2014/42]
Type: B1 Patent specification 
No.:EP2788348
Date:19.10.2016
Language:EN
[2016/42]
Search report(s)International search report - published on:EP13.06.2013
ClassificationIPC:C07D471/04, A61K31/437, A61P11/00
[2014/42]
CPC:
C07D471/04 (EP,CN,RU,US); A61P11/00 (EP); A61P11/06 (EP);
A61P29/00 (EP); A61P43/00 (EP); A61P9/12 (EP);
A61K31/437 (RU) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/42]
Extension statesBA03.06.2014
ME03.06.2014
TitleGerman:KINASE-INHIBITOREN[2014/42]
English:KINASE INHIBITORS[2014/42]
French:INHIBITEURS DE KINASE[2016/23]
Former [2014/42]INHIBITEURS DE KINASES
Entry into regional phase03.06.2014National basic fee paid 
03.06.2014Designation fee(s) paid 
03.06.2014Examination fee paid 
Examination procedure03.06.2014Examination requested  [2014/42]
12.12.2014Amendment by applicant (claims and/or description)
29.01.2016Despatch of a communication from the examining division (Time limit: M04)
14.04.2016Reply to a communication from the examining division
24.05.2016Communication of intention to grant the patent
06.09.2016Fee for grant paid
06.09.2016Fee for publishing/printing paid
06.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  29.01.2016
Opposition(s)20.07.2017No opposition filed within time limit [2017/39]
Fees paidRenewal fee
29.12.2014Renewal fee patent year 03
28.12.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU05.12.2012
AL19.10.2016
AT19.10.2016
BE19.10.2016
CY19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
MC19.10.2016
MK19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SI19.10.2016
SK19.10.2016
SM19.10.2016
IE05.12.2016
LU05.12.2016
MT05.12.2016
CH31.12.2016
LI31.12.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
[2020/34]
Former [2018/43]HU05.12.2012
AT19.10.2016
BE19.10.2016
CY19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
MC19.10.2016
MK19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SI19.10.2016
SK19.10.2016
SM19.10.2016
IE05.12.2016
LU05.12.2016
MT05.12.2016
CH31.12.2016
LI31.12.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2018/30]HU05.12.2012
AT19.10.2016
BE19.10.2016
CY19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
MC19.10.2016
MK19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SI19.10.2016
SK19.10.2016
SM19.10.2016
IE05.12.2016
LU05.12.2016
CH31.12.2016
LI31.12.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/49]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
MC19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SI19.10.2016
SK19.10.2016
SM19.10.2016
IE05.12.2016
LU05.12.2016
CH31.12.2016
LI31.12.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/42]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
MC19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SK19.10.2016
SM19.10.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/38]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SK19.10.2016
SM19.10.2016
BG19.01.2017
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/37]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SK19.10.2016
SM19.10.2016
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/36]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
EE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RO19.10.2016
RS19.10.2016
SE19.10.2016
SK19.10.2016
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/34]AT19.10.2016
BE19.10.2016
CZ19.10.2016
DK19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RS19.10.2016
SE19.10.2016
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/33]AT19.10.2016
BE19.10.2016
DK19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RS19.10.2016
SE19.10.2016
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/26]AT19.10.2016
BE19.10.2016
ES19.10.2016
FI19.10.2016
HR19.10.2016
LT19.10.2016
LV19.10.2016
NL19.10.2016
PL19.10.2016
RS19.10.2016
SE19.10.2016
NO19.01.2017
GR20.01.2017
IS19.02.2017
PT20.02.2017
Former [2017/12]LV19.10.2016
Cited inInternational search[YD]WO2007091152  (PFIZER LTD [GB], et al) [YD] 1-16 * page 1, line 9 - line 13; examples 1-11; claim 1 *;
 [YD]WO2010094956  (PULMAGEN THERAPEUTICS INFLAMMA [GB], et al) [YD] 1-16* examples 14-16; claim 1; tables 1,2 *
by applicantEP0505321
 WO9702289
 WO9703094
 EP1052264
 WO0104115
 WO0242298
 EP1241176
 WO03053930
 WO2004072072
 US2004192653
 WO2005026124
 EP1609789
 WO2006009741
 US2006035922
 WO2006018727
 WO2006082412
 WO2006133006
 WO2007091152
 WO2008033999
 WO2008034008
 WO2008043019
 US2008113967
 WO2008063287
 WO2008125014
 WO2009022633
 WO2009048474
 WO2009150614
 WO2010022076
 WO2010068258
 WO2010077836
 WO2010094956
 WO2010108058
 WO2011018916
 WO2011042389
 WO2011070368
    - STEIN ET AL., ANN. REP. MED CHEM., (1996), vol. 31, pages 289 - 298
    - HERLAAR E.; BROWN Z., MOLECULAR MEDICINE TODAY, (1999), vol. 5, pages 439 - 447
    - DINARELLO ET AL., REV. INFECT. DISEASE, (1984), vol. 6, page 51
    - BADGER ET AL., J. PHARM. EXP. THERA., (1996), vol. 279, pages 1453 - 1461
    - GRISWOLD ET AL., PHARMACOL. COMM., (1996), vol. 7, pages 323 - 229
    - HADDAD ET AL., BR. J. PHARMACOL., (2001), vol. 132, no. 8, pages 1715 - 1724
    - UNDERWOOD ET AL., AM. J. PHYSIOL. LUNG CELL. MOL., (2000), vol. 279, pages 895 - 902
    - DUAN ET AL., AM. J. RESPIR. CRIT. CARE MED., (2005), vol. 171, pages 571 - 578
    - ESCOTT ET AL., BR. J. PHARMACOL., (2000), vol. 131, pages 173 - 176
    - UNDERWOOD ET AL., J. PHARMACOL. EXP. THER., (2000), vol. 293, pages 281 - 288
    - LEE ET AL., IMMUNOPHARMACOLOGY, (2000), vol. 47, pages 185 - 200
    - P. CHOPRA ET AL., EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2008), vol. 17, no. 10, pages 1411 - 1425
    - G. J. HANSON, EXPERT OPINIONS ON THERAPEUTIC PATENTS, (1997), vol. 7, pages 729 - 733
    - J HYNES ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2005), vol. 5, pages 967 - 985
    - C. DOMINGUEZ ET AL., EXPERT OPINIONS ON THERAPEUTICS PATENTS, (2005), vol. 15, pages 801 - 816
    - L. H. PETTUS; R. P. WURTZ, CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2008), vol. 8, pages 1452 - 1467
    - T. HIGUCHI; V.J. STELLA, Pro-drugs as Novel Delivery Systems, vol. 14
    - E. B. ROCHE,, Bioreversible Carriers in Drug Design, PERGAMON PRESS
    - J. MED CHEM., (2007), vol. 50, page 4016
    - BULLETIN DES SOCIETES CHIMIQUES BELGES, (1987), vol. 96, pages 675 - 709
    - ORGANIC & BIOMOLECULAR CHEMISTRY, (2006), vol. 4, pages 4158 - 4164
    - CHEMISTRY-A EUROPEAN JOURNAL, (2011), vol. 17, pages 6606 - 6609,56606,1-S6606,38
    - JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS, (1985), vol. 1, pages 2039 - 44
    - JOURNAL OF ORGANIC CHEMISTRY, (2007), vol. 72, pages 669 - 671
    - TETRAHEDRON LETTERS, (2011), vol. 52, pages 1310 - 1312
    - ORGANIC LETTERS, (2002), vol. 4, pages 3423 - 3426
    - ANGEWANDTE CHEMIE, INTERNATIONAL EDITION, (2006), vol. 45, pages 98 - 101
    - CHIMIA, (2007), vol. 61, pages 169 - 171
    - EYLES JE; WILLIAMSON ED; ALPAR HO., INT J PHARM, (1999), vol. 189, no. 1, pages 75 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.